/INTI
INTI Stock - Inhibitor Therapeutics, Inc.
Healthcare|BiotechnologyOTC
$0.04-7.79%
$0.00 (-7.79%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.22
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.05
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INTI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.04 – $0.05
TARGET (TP)$0.05
STOP LOSS$0.04
RISK/REWARD1:1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.52
52W High$0.08
52W Low$0.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-3,657,000 | $-3,405,000 | $-658,000 | $-325,000 | $-1,059,000 |
| Net Income | $-3,339,000 | $-3,026,000 | $12.11M | $-299,000 | $-1,057,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.02 | $-0.02 | $0.03 | $-0.00 | $-0.00 |
Company Overview
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
INTIBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-0.00 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-0.00 | — | — |
Q2 2025 | May 14, 2025 | — | $-0.00 | — | — |
Q1 2025 | Mar 28, 2025 | — | $-0.01 | — | — |
Q4 2024 | Nov 12, 2024 | — | $-0.00 | — | — |
Q3 2024 | Aug 6, 2024 | — | $-0.00 | — | — |
Q2 2024 | May 13, 2024 | — | $-0.00 | — | — |
Q1 2024 | Mar 29, 2024 | — | $-0.01 | — | — |
Q4 2023 | Nov 13, 2023 | — | $-0.00 | — | — |
Q3 2023 | Aug 11, 2023 | — | $-0.00 | — | — |
Q2 2023 | May 15, 2023 | — | $-0.00 | — | — |
Q1 2023 | Mar 31, 2023 | — | $0.04 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-0.00 | — | — |
Q3 2022 | Aug 12, 2022 | — | $-0.00 | — | — |
Q2 2022 | May 13, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.00 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-0.00 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-0.00 | — | — |
Q2 2021 | May 14, 2021 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about INTI
What is INTI's current stock price?
Inhibitor Therapeutics, Inc. (INTI) is currently trading at $0.04 per share. The stock has moved -7.79% today.
What is the analyst price target for INTI?
No analyst price targets are currently available for this stock.
What sector is Inhibitor Therapeutics, Inc. in?
Inhibitor Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is INTI's market cap?
Inhibitor Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does INTI pay dividends?
No, Inhibitor Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBETRF
BetterLife Pharma Inc.
$0.04
Mkt Cap: $0.0B
CHMMF
Chimeric Therapeutics Limited
$0.00
Mkt Cap: $0.0B
CUBT
Curative Biotechnology, Inc.
$0.01
Mkt Cap: $0.0B
DVHGF
Devonian Health Group Inc.
$0.07
Mkt Cap: $0.0B
LIANY
LianBio
$0.11
Mkt Cap: $0.0B
NSVGF
Nass Valley Gateway Ltd.
$0.01
Mkt Cap: $0.0B
NYMXF
Nymox Pharmaceutical Corporation
$0.07
Mkt Cap: $0.0B
OXBOF
Oxford BioDynamics Plc
$0.00
Mkt Cap: $0.0B
PHRRF
PharmaTher Holdings Ltd.
$0.08
Mkt Cap: $0.0B
QNNTF
Quantum Genomics S.A.
$0.10
Mkt Cap: $0.0B
Explore stocks similar to INTI for comparison